<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

1 min read

A Roller Coaster Quarter: Q220 OrthoBio Market Recap

By Kim French on 10/7/20 9:30 AM

Calibrating the craziness and uncertainties of a roller coaster quarter

Because Orthobiologics spans various markets and is used in numerous procedures in different surgical settings, Q2 proved to be a roller coaster of a quarter, creating uncertainty and craziness. Beginning in mid-March with stay-at-home orders and restrictions on elective surgery, US elective procedures bottomed in April, resulting in plummeting revenues and increased angst.

Responding quickly to the new twists and turns of COVID-19, many companies shifted priorities, reduced costs and implemented initiatives to help climb out of the record-breaking descent of Q220. Revenue and procedural recovery varied widely and impacted segments differently.

Among the many topics covered in the comprehensive Q220 OrthoBio  Market Recap* are:

Continue Reading
2 min read

COVID Clobbers Companies: Q220 US Joint Fluid Replacement Market Recap

By Freddy Buntoum on 9/25/20 11:12 AM

Heavy-weight contender ​COVID-19 landed some brutal blows to revenue in Q220, but companies look for better days in the second half of 2020. 

The impact of the COVID-19 crisis started to hit the US Joint Fluid Replacement market late in Q120, and, to some degree, this helped to shield HA companies from heavy punches to revenue. Although none were left KO’d in round one, they still came through bruised up. Going into Q220 for round two, HA companies prepared as best as they could and braced for impact. Unfortunately, COVID-19 is a formidable opponent and even with strong cost-control measures in place, companies were hit hard with huge revenue losses for products in the three largest segments of the US Joint Fluid Replacement market.


Among the many topics covered in the comprehensive Q220 US Joint Fluid Replacement Market Recap* are:

Continue Reading
6 min read

Q120 Computer Assisted Surgery Ortho Revenue Hit with 1-2 Punch

By Elise Wolf on 7/16/20 10:12 AM

 

Companies came out of the gate strong in Q120, but COVID-19’s one-two punch on elective procedures and capital equipment purchases negatively impacted orthopedic enabling technology revenues toward the end of the quarter.

While adoption of robotics and other enabling technologies was gaining significant momentum quarter over quarter through year-end 2019, delays in elective spine surgery due to the COVID-19 pandemic resulted in declines in capital equipment sales and fewer computer-assisted orthopedic surgeries in Q120.

Among the many topics covered in the comprehensive Q120 CAS Ortho Market Recap* are:

Continue Reading
9 min read

Novel Ideas, New Products and Innovative Studies: The Week in OrthoBio

By Thomas Wallick on 7/14/20 8:00 AM

The orthobiologics market continues to ramp up studies and new product development as surgeries impacted by COVID-19 are rescheduled. The following is a small sampling of the OrthoBio updates compiled, reviewed and posted in real time last week by our SmartTRAK analysts. We constantly monitor  the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, financial data and competitor developments in the global Life Sciences industry.

KAPPA Opiod - Possible DMOAD? 

KECK Medicine of USC has published a preclinical study demonstrating the potential of a new opioid medication that may slow OA progression while being less addictive. The therapy MOA is kappa opioid receptor (KOR) modulation via inhibition of hedgehog signaling. Arthritis Rheum

Association of SNPs in MMPs Genes and Knee OA

A 200-pt prospective, case-control study is underway to assess if the presence of gene polymorphisms (1575 G/A MMP-2, 836 A/G MMP-9 and -77 A/G MMP-13) in the metalloproteinases (MMPs) affect the risk of developing idiopathic kOA in the Greek population. clinicaltrials.gov

National Rates and Risk Factors of Failed Primary RCR

An insurance database review w/ 41,467 primary RCR pts (41,844 shoulders) showed 52.7% male, 60-69 yrs of age most prevalent (~38%) and 8.38% revision rate. Revision risk factors were increasing age, male sex, smoking, obesity, hyperlipidemia and vitamin D deficiency. Arthroscopy

Continue Reading
4 min read

Back Down the Revenue Track: Q120 Soft Tissue Fixation Market Recap

By Freddy Buntoum on 7/10/20 10:37 AM

A well-oiled engine, the Soft Tissue Fixation train was prepped for a good start to 2020, then COVID-19 sent it in reverse back down the revenue tracks.

Looking back at how 2019 finished, market sentiment was quite optimistic that 2020 could be another positive year for the WW Soft Tissue Fixation Market. With +3.7% YoY growth in Q419, the first quarter of 2020 seemed set for a good start, with companies chugging along nicely, actively pushing products, planning or recruiting for clinical trials, and some of them also receiving FDA 510(k) clearance for new products or for line extensions. All appeared to be business as usual, that is, until COVID-19 reared its ugly head, picking China as its first target. Alas, the rapid worldwide spread of this devastating virus forced a major halt in elective procedures to enable healthcare systems to focus on the rising number of COVID-19 cases. 

Among the many topics covered in the comprehensive Q120 Soft Tissue Fixation Market Recap* are:

Continue Reading
7 min read

Mid-March Madness of COVID-19: Q120 OrthoBio Market Recap

By Kim French on 7/8/20 9:30 AM

The mid-March madness of COVID-19 results in final missed shots for many companies.

For sports fans, March is about celebrating the best in college basketball. Regrettably, March Madness was swapped with COVID-19 mid-March madness, disrupting lives and companies across the world. Since the COVID-19 outbreak, the first corporate earnings season has concluded and we now have a peek of the negative impacts caused by the pandemic and deferral of elective procedures. As for Q120, US orthobiologics revenue declined -5.5% YoY compared to Q119. 


Among the many topics covered in the comprehensive 
Q120 OrthoBio Market Recap* are:

Continue Reading
6 min read

Q120 US Joint Fluid Replacement Market: Riding Out the COVID-19 Storm

By Freddy Buntoum on 6/8/20 5:35 PM

Coming through Q120 bruised and expecting much harder punches before the calm, companies ride the COVID-19 storm

According to SmartTRAK Financial Dashboard, Q120 revenue for the US Joint Fluid Replacement market was down -2.8%, which is within the range predicted by market leaders and physicians in SmartTRAK’s Impact of COVID-19 on the US Joint Fluid Replacement and Regenerative Medicine Injectable Markets for Knee OA*. Albeit revenue is down for Q120, the stay-at-home orders across US states triggered by the rapid spread of COVID-19 were not implemented until mid-March, which helped to mitigate what could have been much bigger losses. 

Among the many topics covered in the comprehensive Q120 US Joint Fluid Replacement Market Recap* are:

Continue Reading
4 min read

This Week in Ortho: Projecting the Market's COVID-19 Recovery

By Thomas Wallick on 6/1/20 6:53 PM

As access to healthcare continues to open up, the orthopedic industry is taking significant precautions to insure the health, safety and piece of mind of patients and caregivers and balance that with its attempt to ramp up services and procedures. The following is a small sampling of the orthopedic updates compiled, reviewed and posted in real-time by our SmartTRAK analysts, who are constantly monitoring the situation and sifting through the noise to present the most relevant news to our subscribers:

Updated Survey Data Points to Recovery by Q420

WFS’ new survey of 623 US-based physicians (15 specialties) shows that in orthopedic, the % of procedures expected to be postponed due to COVID-19 for both TKR and THR declined from 94% (Wave 1) to 85% (Wave 2). WFS MedTec: Updated Survey Data Points to Recovery by Q420

Impact of COVID-19 on the Spine Market

Of deferred spinal fusion procedures, surveyed surgeons now expect 74% of cases to be performed at a later date w/ 26% cancelling. Reasons for cancellation include pt seeking treatment w/ a different surgeon (26%) and underlying condition improving (23%). WFS MedTech Survey

Robotic Procedures Affected by COVID-19

Based on its survey of 623 US-based physicians across 15 specialties between April 27 and May 8, WFS notes that in general the % of robotic & laparoscopic procedures across all specialties declined compared to pre-COVID 19 levels, while the % of open procedures increased.

Continue Reading
5 min read

Biomedical Solutions: An Interview with DSM Biomedical's John Witkowski

By Kim French on 5/20/20 10:00 AM

SmartTRAK discusses the latest advancements in biomedical solutions with DSM President John Witkowski

DSM, a global leader in biomedical solutions for more than 30 years, helps improve the health of 3.5 million patients annually. While biomaterials have been around for decades, DSM Biomedical is advancing biomaterial science, providing the latest synthetic biomaterials and stem cell-based technologies that are used in various applications, including spine, general orthopedics, sports medicine, general surgery and wound.

To learn more about the latest advancements in DSM Biomedical biomaterials and technologies and what’s next for the business, click on the following video to listen to SmartTRAK’s interview with John Witkowski, President of DSM Biomedical. A transcript of the interview can also be downloaded below. 

Continue Reading
3 min read

Weathering the COVID-19 Storm in Orthobiologics: An Interview with Steven Sampson, DO

By Freddy Buntoum on 5/11/20 9:00 PM

The COVID-19 pandemic is having a significant effect on physician practices in Orthopedics and Sports Medicine, including the number of elective procedures being postponed, when normal operations might resume, the adoption of telemedicine, delivery of physician education and interactions with industry. To find out more, SmartTRAK Analyst Freddy Buntoum interviewed Steven Sampson, DO, founder of The Orthobiologic Institute (TOBI) and an internationally-recognized expert in the field of non-surgical orthopedics and the science of sports medicine. To hear Dr. Sampson’s take on how things might evolve throughout the rest of 2020, and how his practice and organization are supporting patients and other stakeholders, click on the following video to listen to the interview recorded via Uberconference (25:20 minutes). A transcript of the interview can be downloaded below.

Continue Reading

    Recent Articles